Retatrutide / Cagrilintide

Product Description Retatrutide / Cagrilintide Blend is a research combination containing 5mg Retatrutide (triple agonist of GLP-1, GIP, and glucagon receptors) and 5mg Cagrilintide (long-acting amylin analog) per vial. Supplied as ≥98% pure lyophilized powder (HPLC/MS verified), it is designed for laboratory studies on synergistic effects in appetite regulation, energy expenditure, and metabolic homeostasis.

Key Research Mechanism Retatrutide activates GLP-1, GIP, and glucagon receptors to promote insulin secretion, reduce appetite, increase energy expenditure, and enhance fat metabolism. Cagrilintide mimics amylin by binding to amylin and calcitonin receptors, slowing gastric emptying, increasing satiety via central pathways, and suppressing glucagon. Together, the blend targets complementary pathways for amplified effects on body weight, glucose control, and lipid metabolism in research models.

Primary Research Areas

• Synergistic weight loss and obesity models (appetite suppression and energy expenditure)
• Metabolic health and glucose homeostasis studies
• Body composition, fat metabolism, and lean mass preservation
• Multi-hormone pathway research for enhanced satiety and gastric regulation

Intended Use For in vitro and in vivo research only. Not for human or veterinary use. This product is sold strictly for scientific and laboratory investigation. Researchers must follow all institutional and regulatory guidelines. Not evaluated by the FDA.